companiesandmarkets.com

Summary: Introduction

HGS has a broad portfolio of product candidates which are under clinical development for use in large therapeutic categories including immunology, infectious disease and oncology.

The company has three products advancing into late-stage clinical development: Albuferon for chronic hepatitis C, Lymphostat-B for systemic lupus erythematosus, and Abthraxtm for anthrax disease.

The company’s biggest contributor to sales growth out to 2010 continues to be revenues from R&D contracts. Revenues from R&D contracts are expected to increase at a CAGR of 61%, from $26 million in 2006 to $172 million in 2010. Revenue from product sales includes, Albuferon and LymphoStat- B which is expected to be launched in 2010.

Scope

Reports are normally delivered on the same day, via email, if purchased by debit/credit card. Reports purchased by invoice will be released when payment has been received. When you place an order through Google Checkout, Google Checkout will display a price approximation in your local currency. Keep in mind that you'll still be charged in the currency displayed on companiesandmarkets.com. Your debit/credit card company might convert the charge to your local currency and may also add additional fees that are not reflected in the approximate price displayed.

www.companiesandmarkets.com is a central source of market research reports from the world’s leading analysts and report publishers. Companiesandmarkets.com contains a comprehensive range of specialised market research reports from leading publishers for all market sectors.